Nuvation Bio Inc. (NUVB) Debt Components
- 2026-06-30: Short-term DebtUSD $5.89M; Secured DebtUSD (m); Long-term DebtUSD $242.62M; Long-Term Debt, Maturity, Year OneUSD (m).
- 2026-03-31: Short-term DebtUSD $5.79M; Secured DebtUSD (m); Long-term DebtUSD $47.33M; Long-Term Debt, Maturity, Year OneUSD $3.82M.
- 2025-12-31: Short-term DebtUSD $5.72M; Secured DebtUSD (m); Long-term DebtUSD (m); Long-Term Debt, Maturity, Year OneUSD (m).
- 2025-12-31: Short-term DebtUSD (m); Secured DebtUSD (m); Long-term DebtUSD $47.21M; Long-Term Debt, Maturity, Year OneUSD $5.07M.
Nuvation Bio Inc. Debt Components
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Short-term Debt USD | Secured Debt USD | Long-term Debt USD | Long-Term Debt, Maturity, Year One USD | Long-Term Debt, Maturity, Year Two USD | Long-Term Debt, Maturity, Year Three USD | Long-Term Debt, Maturity, Year Four USD | Long-Term Debt, Maturity, Year Five USD | Long-Term Debt, Maturity, Remainder of Fiscal Year USD | Debt Instrument, Face Amount USD | Line of Credit Assumed USD | Notes Payable, Related Parties, Current USD | Notes Payable, Related Parties, Noncurrent USD |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $5.89M | (m) | $242.62M | (m) | (m) | (m) | (m) | (m) | (m) | $250.00M | (m) | (m) | (m) |
| 2026-03-31 | $5.79M | (m) | $47.33M | $3.82M | $5.07M | $5.08M | $5.07M | $54.04M | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $5.72M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | (m) | (m) | $47.21M | $5.07M | $5.07M | $5.08M | $5.07M | $54.04M | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | $5.62M | (m) | $47.09M | $5.22M | $5.22M | $5.23M | $5.22M | $54.15M | $1.31M | (m) | (m) | (m) | (m) |
| 2025-06-30 | $5.58M | (m) | $46.97M | $5.23M | $5.23M | $5.24M | $5.23M | $54.16M | $2.64M | (m) | (m) | (m) | (m) |
| 2025-03-31 | (m) | $100.00M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $5.68M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-03-03 | (m) | $100.00M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $6.28M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $8.43M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $11.63M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 3 month · $13.62M | (m) | (m) |
| 2023-12-31 | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $80.00K | $80.00K |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |